Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Tectonic Therapeutic, Inc. (NASDAQ: TECX) has announced a significant $185 million private placement financing. The private ...

Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Tectonic Therapeutic (NASDAQ:TECX) has announced a ~$185M capital raise to fund the clinical development of its drug candidates. Pursuant to the terms of the securities purchase agreement, at the ...

WATERTOWN, Mass. - Tectonic Therapeutic, Inc. (NASDAQ: TECX), a biotechnology company specializing in the development of therapeutic proteins and antibodies, announced today that it has entered into a ...

Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Tectonic will issue an aggregate of 3,689,465 shares of common stock at a price of $50.00 per share to fund ...

Tectonic Therapeutic (TECX) announced that it has entered into a securities purchase agreement for a private investment in public equity ...

Schools were closed and emergency crews deployed on the volcanic Greek island of Santorini on Monday after a spike in seismic ...

Tectonic Therapeutic (NASDAQ:TECX – Free Report) had its price objective raised by Wells Fargo & Company from $79.00 to $112.00 in a research report report published on Friday morning,Benzinga reports ...